Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Five Prime Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million.
Five Prime Therapeutics, Inc. is a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics. Five Prime's discovery platform positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology.
The Davis Polk corporate team included partner Emily Roberts and associate Jonathan Bye. Partner Mario J. Verdolini and associate Tomislava Dragicevic provided tax advice. Partner David R. Bauer and associate Jennifer Leather provided intellectual property advice. Associate Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.